Information:
Error:
ID
17833
Description
Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult); ODM derived from: https://clinicaltrials.gov/show/NCT00456027
Link
https://clinicaltrials.gov/show/NCT00456027
Keywords
Versions (1)
- 10/4/16 10/4/16 -
Uploaded on
October 4, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Latent Autoimmune Diabetes in Adult (LADA) NCT00456027
Eligibility Latent Autoimmune Diabetes in Adult (LADA) NCT00456027
- StudyEvent: Eligibility
Similar models
Eligibility Latent Autoimmune Diabetes in Adult (LADA) NCT00456027
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Age | Diabetes Mellitus, Non-Insulin-Dependent
Item
male and female patients between 30-70 years of age diagnosed with type 2 diabetes within 5 years
boolean
C0001779 (UMLS CUI [1])
C0011860 (UMLS CUI [2])
C0011860 (UMLS CUI [2])
Serum Gad65 Auto Antibodies Test Positive
Item
presence of gad65 antibodies
boolean
C1255118 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
C1514241 (UMLS CUI [1,2])
C-peptide level Detectable
Item
detectable c-peptide level
boolean
C0202100 (UMLS CUI [1,1])
C3830527 (UMLS CUI [1,2])
C3830527 (UMLS CUI [1,2])
Diet therapy Patient need for | Oral hypoglycemic Patient need for
Item
patients requiring treatment with diet and/or oral hypoglycaemic agents (oha)
boolean
C0012159 (UMLS CUI [1,1])
C0686904 (UMLS CUI [1,2])
C0359086 (UMLS CUI [2,1])
C0686904 (UMLS CUI [2,2])
C0686904 (UMLS CUI [1,2])
C0359086 (UMLS CUI [2,1])
C0686904 (UMLS CUI [2,2])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
C1542147 (UMLS CUI [1,2])
Insulin regime
Item
treatment with insulin
boolean
C0557978 (UMLS CUI [1])
intolerance to Oral hypoglycemic
Item
intolerance to oha
boolean
C1744706 (UMLS CUI [1,1])
C0359086 (UMLS CUI [1,2])
C0359086 (UMLS CUI [1,2])
Secondary diabetes mellitus
Item
secondary diabetes mellitus
boolean
C0271640 (UMLS CUI [1])
Disease Any | medical condition Any | Anemia | Epilepsy | Craniocerebral Trauma | nervous system disorder | Substance Use Disorders | HIV | Hepatitis
Item
history of certain diseases or conditions (e.g. anaemia, epilepsy, head trauma, neurological disease, alcohol or drug abuse, hiv, hepatitis)
boolean
C0012634 (UMLS CUI [1,1])
C1552551 (UMLS CUI [1,2])
C3843040 (UMLS CUI [2,1])
C1552551 (UMLS CUI [2,2])
C0002871 (UMLS CUI [3])
C0014544 (UMLS CUI [4])
C0018674 (UMLS CUI [5])
C0027765 (UMLS CUI [6])
C0038586 (UMLS CUI [7])
C0019682 (UMLS CUI [8])
C0019158 (UMLS CUI [9])
C1552551 (UMLS CUI [1,2])
C3843040 (UMLS CUI [2,1])
C1552551 (UMLS CUI [2,2])
C0002871 (UMLS CUI [3])
C0014544 (UMLS CUI [4])
C0018674 (UMLS CUI [5])
C0027765 (UMLS CUI [6])
C0038586 (UMLS CUI [7])
C0019682 (UMLS CUI [8])
C0019158 (UMLS CUI [9])
Vaccine Any | Glutamate decarboxylase 65 Dose Ordinal number
Item
treatment with any vaccine within one month prior to first diamyd® dose or planned treatment with vaccine up to 2 months after the second diamyd® dose
boolean
C0042210 (UMLS CUI [1,1])
C1552551 (UMLS CUI [1,2])
C1291583 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0439080 (UMLS CUI [2,3])
C1552551 (UMLS CUI [1,2])
C1291583 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0439080 (UMLS CUI [2,3])
Study Subject Participation Status | Chemicals Investigational
Item
participation in other clinical trials with a new chemical entity within the previous 3 months
boolean
C2348568 (UMLS CUI [1])
C0220806 (UMLS CUI [2,1])
C1517586 (UMLS CUI [2,2])
C0220806 (UMLS CUI [2,1])
C1517586 (UMLS CUI [2,2])
Pregnancy | Pregnancy, Planned
Item
pregnancy (or planned pregnancy within one year after 2nd administration)
boolean
C0032961 (UMLS CUI [1])
C0032992 (UMLS CUI [2])
C0032992 (UMLS CUI [2])
Comorbidity Serious Study Subject Participation Status Ineligible | medical condition Serious Study Subject Participation Status Ineligible
Item
presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study
boolean
C0009488 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C1512714 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
C1512714 (UMLS CUI [2,4])
C0205404 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C1512714 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
C1512714 (UMLS CUI [2,4])
Illness Significant | Diabetes Mellitus
Item
significant illness other than diabetes within 2 weeks prior to first dosing
boolean
C0221423 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0011849 (UMLS CUI [2])
C0750502 (UMLS CUI [1,2])
C0011849 (UMLS CUI [2])
Protocol Compliance Unwilling
Item
unwillingness to comply with the provisions of the protocol
boolean
C0525058 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,2])
Acute allergic reaction Clinical Significant Pharmaceutical Preparations
Item
clinically significant history of acute reaction to drugs in the past
boolean
C0413234 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C2826293 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
Immunosuppressive Agents
Item
treatment with immunosuppressants
boolean
C0021081 (UMLS CUI [1])